Cargando…
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
INTRODUCTION: Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown. METHODS: In two placebo-controlled studies in patients with blunt and penetrating trauma, the pharmacokinetics o...
Autores principales: | Klitgaard, Thomas, y Palacios, Rene Tabanera, Boffard, Kenneth D, Iau, Philip TC, Warren, Brian, Rizoli, Sandro, Rossaint, Rolf, Kluger, Yoram, Riou, Bruno |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1750999/ https://www.ncbi.nlm.nih.gov/pubmed/16859505 http://dx.doi.org/10.1186/cc4977 |
Ejemplares similares
-
Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
por: Rizoli, Sandro B, et al.
Publicado: (2006) -
Cost-effectiveness analysis of recombinant activated factor VII as adjunctive therapy for bleeding control in severely injured trauma patients in Germany
por: Rossaint, R, et al.
Publicado: (2006) -
A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005) -
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
por: Kluger, Yoram, et al.
Publicado: (2007) -
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
por: Vincent, Jean-Louis, et al.
Publicado: (2006)